IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS Russian patent published in 2015 - IPC A61K31/497 

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and can be used for application of TOR-kinase inhibitor for obtaining medication for treatment of non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers syndrome. For this purpose effective quantity of TOR-kinase inhibitor, representing 7-(6-(2-hydroxypropan-2-yl)pyridine-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridine-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or its pharmaceutically acceptable salt is introduced to patient. Pharmaceutical composition and sets for treatment of diseases, application for prediction of probability of patient's response to therapy with TOR-kinase inhibitor, application for prediction of therapeutic efficiency of treatment with TOR-kinase inhibitor are also claimed.

EFFECT: group of inventions provides diagnostics and treatment of non-small lung carcinoma, cervical cancer, Peutz-Jeghers syndrome, which are characterised by absence or mutation of gene or protein LKB1 and/or AMPK in comparison with wild type.

25 cl, 7 dwg